Immune reconstitution in human immunodeficiency virus-positive patients on highly active antiretroviral therapy at an urban public sector district hospital

被引:0
作者
Jimoh, O. S. [1 ]
Naidoo, M. [1 ]
机构
[1] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Family Med, Durban, South Africa
关键词
immune reconstitution; baseline; CD4 T-cell count; virological suppression; retrospective descriptive study; HAART;
D O I
10.1080/23120053.2014.11441580
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Immune reconstitution is measured by circulating CD4 T cells that follows a biphasic pattern. Not everyone who is on highly active antiretroviral therapy (HAART) will attain immune reconstitution at the same rate, or to the same extent. This study aimed to describe the patterns of immune reconstitution in an urban public district hospital. A retrospective review of clinical files was performed on 354 patients who maintained virological suppression to <50 copies/ml over three years, following the initiation of HAART. Changes in CD4 T-cell count were described using descriptive statistics. Non-parametric analysis was conducted. Ninety-four per cent (n = 334) of patients had a baseline CD4 count <= 200 cells/ul, while only 0.3% (n = 1) had a baseline >350 cells/ul. The CD4 count increased from a median baseline of 92 cells/ul to 429 cells/ul over the three-year period. The CD4 count increased by 184 cells/ul, 72 cells/ul and 62 cells/ul in the first, second and third years, respectively. At the last determination, 37.3% (132) had a CD4 count >= 500 cells/ul and 6.8% (24) had a CD4 count <200 cells/ul. Females had a statistically significant (p-value <0.001) overall increase of 349 cells/ul, compared to the 273 cells/ul seen in males. Only 27.6% (53) of patients with a baseline CD4 cell count <100 cells/ul were able to attain levels >= 500 cells/ul. Despite the good response to HAART, patients with a baseline CD4 cell count <100 cells/ul were less likely to attain a normal CD4 count after three years of virological suppression on HAART than those with a higher baseline. (C) SAJID
引用
收藏
页码:105 / 109
页数:5
相关论文
共 50 条
[21]   Reconstitution of thymic function in HIV-1 patients treated with highly active antiretroviral therapy [J].
Ye, P ;
Kourtis, AP ;
Kirschner, DE .
CLINICAL IMMUNOLOGY, 2003, 106 (02) :95-105
[22]   Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting [J].
Colombo, Giorgio L. ;
Castagna, Antonella ;
Di Matteo, Sergio ;
Galli, Laura ;
Bruno, Giacomo ;
Poli, Andrea ;
Salpietro, Stefania ;
Carbone, Alessia ;
Lazzarin, Adriano .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 :9-15
[23]   Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era [J].
Cerrato, Enrico ;
D'Ascenzo, Fabrizio ;
Biondi-Zoccai, Giuseppe ;
Calcagno, Andrea ;
Frea, Simone ;
Marra, Walter Grosso ;
Castagno, Davide ;
Omede, Pierluigi ;
Quadri, Giorgio ;
Sciuto, Filippo ;
Presutti, Davide ;
Frati, Giacomo ;
Bonora, Stefano ;
Moretti, Claudio ;
Gaita, Fiorenzo .
EUROPEAN HEART JOURNAL, 2013, 34 (19) :1432-+
[24]   Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy [J].
Shelburne, SA ;
Visnegarwala, F ;
Darcourt, J ;
Graviss, EA ;
Giordano, TP ;
White, AC ;
Hamill, RJ .
AIDS, 2005, 19 (04) :399-406
[25]   Loss of Preexisting Immunological Memory Among Human Immunodeficiency Virus-Infected Women Despite Immune Reconstitution With Antiretroviral Therapy [J].
Thomas, Archana ;
Hammarlund, Erika ;
Gao, Lina ;
Holman, Susan ;
Michel, Katherine G. ;
Glesby, Marshall ;
Villacres, Maria C. ;
Golub, Elizabeth T. ;
Roan, Nadia R. ;
French, Audrey L. ;
Augenbraun, Michael H. ;
Slifka, Mark K. .
JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (02) :243-251
[26]   Dilated cardiomyopathy in two adult human immunodeficiency positive (HIV+) patients possibly related to highly active antiretroviral therapy (HAART) [J].
Breuckmann, F ;
Neumann, T ;
Kondratieva, J ;
Wieneke, H ;
Ross, B ;
Nassenstein, K ;
Barkhausen, J ;
Kreuter, A ;
Brockmeyer, N ;
Erbel, R .
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2005, 10 (09) :395-399
[27]   The use of highly active antiretroviral therapy for the prevention of mother-to-child transmission of the human immunodeficiency virus in Nigeria [J].
Chama, C. M. ;
Bello, M. ;
Ajayi, B. A. ;
Zarma, S. ;
Gashau, W. .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2010, 30 (04) :362-366
[28]   Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection [J].
Childers, Meredith E. ;
Woods, Steven Paul ;
Letendre, Scott ;
McCutchan, J. Allen ;
Rosario, Debralee ;
Grant, Igor ;
Mindt, Monica Rivera ;
Ellis, Ronald J. .
JOURNAL OF NEUROVIROLOGY, 2008, 14 (06) :550-557
[29]   Human Immunodeficiency Virus Infection: Does Highly Active Antiretroviral Therapy Influence Ear Nose Throat Manifestations? [J].
Dosemane D. ;
Kumar V. ;
Madi D. ;
Kanthila J. .
Indian Journal of Otolaryngology and Head & Neck Surgery, 2018, 70 (4) :555-558
[30]   Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections [J].
Hung, CC ;
Chang, SC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (05) :849-853